Overview

BX-1 in Spasticity Due to Multiple Sclerosis

Status:
Completed

Trial end date:
2021-03-30

Target enrollment:

Participant gender:

Summary

To investigate the efficacy and safety of orally administered BX-1 compared to placebo in patients with spasticity due to multiple sclerosis not sufficiently controlled by current anti-spasticity medication

Phase:

Phase 3

Details

Lead Sponsor:

Bionorica SE

Treatments:

Dronabinol